Warfarin in haemodialysis patients with atrial fibrillation: What benefit?

Europace

Volumn 12, Issue 12, 2010, Pages 1666-1672

  Yang, Felix ^a   Chou, Denise ^b   Schweitzer, Paul ^c   Hanon, Sam ^c  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Atrial fibrillation; Haemodialysis; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; WARFARIN;

BLEEDING; BLOOD VESSEL CALCIFICATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CHRONIC DISEASE; HEMORRHAGE; HUMANS; KIDNEY DISEASES; RENAL DIALYSIS; RISK FACTORS; STROKE; WARFARIN;

EID: 78649336758     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euq387     Document Type: Review

References (62)

1. Genovesi S, Pogliani D, Faini A, Valsecchi MG, Riva A, Stefani F et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 2005;46:897-902.
2. Atar I, Konas D, Acikel S, Kulah E, Atar A, Bozbas H et al. Frequency of atrial fibril-lation and factors related to its development in dialysis patients. Int J Cardiol 2006; 106:47-51.
3. Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoa-gulant therapy. Kidney Int 2010;77:1098-106.
4. Vazquez E, Sanchez-Perales C, Borrego F, Garcia-Cortes MJ, Lozano C, Guzman M, et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 2000;140:886-90.
5. Vazquez E, Sanchez-Perales C, Lozano C, Garcia-Cortes MJ, Borrego F, Guzman M et al. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol 2003; 92:868-71.
6. Wiesholzer M, Harm F, Tomasec G, Barbieri G, Putz D, Balcke P. Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol 2001;21:35-9.
7. US Renal Data System: USRDS 2009. Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009.
8. Vazquez E, Sanchez-Perales C, Garcia-Garcia F, Castellano P, Garcia-Cortes MJ, Liebana A et al. Atrial fibrillation in incident dialysis patients. Kidney Int 2009;76: 324-30.
9. To AC, Yehia M, Collins JF. Atrial fibrillation in haemodialysis patients: do the guidelines for anticoagulation apply? Nephrology (Carlton) 2007;12: 441-7.
10. Sohal AS, Gangji AS, Crowther MA, Treleaven D. Uremic bleeding: pathophysiol-ogy and clinical risk factors. Thromb Res 2006;118:417-22.
11. Benigni A, Boccardo P, Galbusera M, Monteagudo J, De Marco L, Remuzzi G et al. Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia. Am J Kidney Dis 1993;22:668-76.
12. Iseki K, Kinjo K, Kimura Y, Osawa A, Fukiyama K Evidence for high riskof cerebral hemorrhage in chronic dialysis patients. Kidney Int 1993;44:1086-90.
13. Bos MJ, Koudstaal PJ, Hofman A, Breteler MM. Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam Study. Stroke 2007;38:3127-32.
14. O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005;46: 200-4.
15. Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG et al. Death and disabilityfromwarfarin-associated intracranialand extracranial hemorrhages. Am J Med 2007;120:700-5.
16. Boyle JM, Johnston B. Acute uppergastrointestinal hemorrhage in patients with chronic renal disease. Am J Med 1983;75:409-12.
17. Holden RM, Harman GJ,Wang M, Holland D, Day AG. Major bleeding in hemo-dialysis patients. Clin J Am Soc Nephrol 2008;3:105-10.
18. Holden RM, Clase CM. Use of warfarin in people with low glomerular filtration rate or on dialysis. Semin Dial 2009;22:503-11.
19. Chachati A, Godon JP. Effect of haemodialysis on upper gastrointestinal tract pathology in patients with chronic renal failure. Nephrol Dial Transplant 1987;1: 233-7.
20. Wyse DG, Waldo AL, Di Marco JP, Domanski MJ, Rosenberg Y, Schron EB et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33
21. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991;84:527-39.
22. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Vali-dation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.JAMA 2001;285:2864-70.
23. Estes NA 3rd, Halperin JL, Calkins H, Ezekowitz MD, Gitman P, Go AS et al. ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults with Nonvalvular Atrial Fibrillation or Atrial Flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Commit-tee to Develop Clinical Performance Measures for Atrial Fibrillation) developed in collaboration with the Heart Rhythm Society. J Am Coll Cardiol 2008;51: 865-84.
24. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. ACC/AHA/ESC 2006 Guidelines forthe Management ofPatients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society ofCardiology Com-mittee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collabor-ation with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-354.
25. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrilla-tion. N Engl J Med 2003;349:1019-26.
26. Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation\friend orfoe? Thromb Haemost; 104:45-8.
27. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratifica-tion for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010;137:263-72.
28. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-67.
29. Lip GY, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med 2010;123:484-8.
30. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrom-botic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
31. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW et al. Atrial fibrillation management a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005;26: 2422-34.
32. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications ofantic-oagulant and thrombolytic treatment American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133: 257S-98S.
33. Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF. Devel-opment of a contemporary bleeding risk model for elderly warfarin recipients. Chest 2006;130:1390-6.
34. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an indexfor predict-ing the riskof major bleeding in outpatients treated with warfarin. Am J Med 1998; 105:91-9.
35. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151:713-9.
36. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest 2010;138: 1093-100.
37. Biggers JA, Remmers ARJr, Glassford DM, Sarles HE, Lindley JD, Fish JC. The risk of anticoagulation in hemodialysis patients. Nephron 1977;18:109-13.
38. O'Shea SI, Lawson JH, Reddan D, Murphy M, Ortel TL. Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg 2003;38:541-8.
39. Le Sar CJ, Merrick HW, Smith MR. Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access. J Am Coll Surg 1999;189:73-9; discussion 9-81.
40. Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis 2007;50:433-40.
41. Sood MM, Komenda P, Sood AR, Rigatto C, Bueti J. The intersection of risk and benefit is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis? Chest 2009;136:1128-33.
42. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009;20:2223-33.
43. Limdi NA, Beasley TM, Baird MF, Goldstein JA, Mc Gwin G, Arnett DK et al. Kidney function influences warfarin responsiveness and hemorrhagic compli-cations. JAm Soc Nephrol 2009;20:912-21.
44. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 2008;4:1065-74.
45. Dreisbach AW, Japa S, Gebrekal AB, Mowry SE, Lertora JJ, Kamath BL et al. Cytochrome P4502C9 activity in end-stage renal disease. Clin Pharmacol Ther 2003;73:475-7.
46. Genovesi S, Vincenti A, Rossi E, Pogliani D, Acquistapace I, Stella A et al. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 2008;51:255-62.
47. Seliger SL, Gillen DL, Longstreth WT Jr, Kestenbaum B, Stehman-Breen CO. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 2003;64:603-9.
48. Shurraw S, Tonelli M. AURORA: is there a role for statin therapy in dialysis patients? Am J Kidney Dis 55:237-40.
49. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:238-48.
50. Fellstrom BC,Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407.
51. Holden RM, Booth SL. Vascular calcification in chronic kidney disease: the role of vitamin K. Nat Clin Pract Nephrol 2007;3:522-3.
52. El-Abbadi M, Giachelli CM. Mechanisms of vascular calcification. Adv Chronic Kidney Dis 2007;14:54-66.
53. Spronk HM, Soute BA, Schurgers LJ, Cleutjens JP, Thijssen HH, De Mey JG et al. Matrix Gla protein accumulates at the border of regions of calcification and normal tissue in the media of the arterial vessel wall. Biochem Biophys Res Commun 2001;289:485-90.
54. Shearer MJ, Bach A, Kohlmeier M. Chemistry, nutritional sources, tissue distri-bution and metabolism of vitamin K with special reference to bone health. J Nutr 1996;126:1181S-6S.
55. Jin DY, Tie JK, Stafford DW. The conversion of vitamin K epoxide to vitamin K quinone and vitamin K quinone to vitamin K hydroquinone uses the same active site cysteines. Biochemistry 2007;46:7279-83.
56. Koos R, Mahnken AH, Muhlenbruch G, Brandenburg V, Pflueger B, Wildberger JE et al. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol 2005;96:747-9.
57. Streit M, Paredes BE, Ruegger S, Brand CU. Typical features of calciphylaxis in a patient with end-stage renal failure, diabetes mellitus and oral anticoagulation. Dermatology 2000;200:356-9.
58. Rudwaleit M, Schwarz A,Trautmann C, Offermann G, Distler A. Severe calciphylaxis in a renal patienton long-term oral anticoagulanttherapy. Am J Nephrol1996;16:344-8.
59. Pineo GF, Hull RD. Adverse effects of coumarin anticoagulants. Drug Saf1993;9: 263-71.
60. Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 2002;61:2210-7.
61. Arseculeratne G, Evans AT, Morley SM. Calciphylaxis\a topical overview. J Eur Acad Dermatol Venereol 2006;20:493-502.
62. Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagno-sis, and treatment Semin Dial 2002;15:172-86.